Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases (Q44794355)

6 December 2017

Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases (English)

1 reference

6 December 2017

1 reference

Terence C Chua

1

1 reference

6 December 2017

Lourens Bester

series ordinal

2

1 reference

6 December 2017

Akshat Saxena

series ordinal

3

1 reference

6 December 2017

David L Morris

series ordinal

4

1 reference

6 December 2017

22 September 2010

1 reference

Journal of Cancer Research and Clinical Oncology

6 December 2017

1 reference

6 December 2017

137

1 reference

6 December 2017

5

1 reference

6 December 2017

865-873

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-010-0948-y

6 December 2017

0 references

cites work

Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Reduction of arteriohepatovenous shunting by temporary balloon occlusion in patients undergoing radioembolization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Treatment of colorectal cancer: hepatic metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Arterial, portal, or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Radioembolization of liver metastases in patients with colorectal cancer: a nonsurgical treatment with combined modality potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Liver metastases from colorectal cancer: radioembolization with systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Expanding criteria for resectability of colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Actual 10-year survival after resection of colorectal liver metastases defines cure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0948-Y

Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy

21 January 2018

1 reference

12 December 2020

The natural history of primary and secondary malignant tumors of the liver I.The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy

1 reference

12 December 2020

Resection of hepatic metastases from colorectal cancer. Biologic perspective

1 reference

12 December 2020

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group

1 reference

12 December 2020

Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity

1 reference

12 December 2020

A retrospective study of the natural history of patients with liver metastases from colorectal cancer

1 reference

12 December 2020

Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?

1 reference

12 December 2020

10.1007/S00432-010-0948-Y

Identifiers

DOI

1 reference

6 December 2017

1 reference